PARIS--(BUSINESS WIRE)--BrightHeart, a Paris-based company developing an AI solution for the prenatal detection of congenital heart defects, announced today the appointment of Michael Butchko as an ...

PARIS, September 02, 2025--(BUSINESS WIRE)--BrightHeart, a pioneer in AI-driven prenatal ultrasound evaluation, today announced the publication of its landmark study in Obstetrics & Gynecology, ...

PARIS, January 31, 2025--(BUSINESS WIRE)--BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during ...

BrightHeart has gained a further 510(k) clearance from the US Food and Drug Administration (FDA) for its AI-based prenatal congenital heart defect (CHD) screening platform. Building on the initial FDA ...

BrightHeart’s AI-based software for prenatal congenital heart defect (CHD) screening has demonstrated promise in two new ...

BrightHeart's technology is claimed to be alleviating the strain on overburdened sonographers and OB/GYNs. Credit: Andrey_Popov / Shutterstock. BrightHeart has received the US Food and Drug ...

PARIS, FRANCE / ACCESSWIRE / May 31, 2023 / BrightHeart, a Paris-based medical technology company developing unique artificial intelligence software focused on improving the detection of congenital ...

BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, announced today the 510(k) clearance for updates to the BrightHeart platform, adds the ...

BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on ...